Production (Stage)
Collegium Pharmaceutical, Inc.
COLL
$29.84
$0.662.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.42M | 12.54M | 9.34M | 19.61M | 27.71M |
| Total Depreciation and Amortization | 56.56M | 56.51M | 41.75M | 35.47M | 35.43M |
| Total Amortization of Deferred Charges | 1.37M | 1.42M | 1.21M | 1.60M | 1.78M |
| Total Other Non-Cash Items | 10.75M | -2.64M | 2.67M | 12.94M | 2.63M |
| Change in Net Operating Assets | -15.70M | 16.81M | -63.95M | -2.22M | -5.62M |
| Cash from Operations | 55.40M | 84.64M | -9.00M | 67.40M | 61.94M |
| Capital Expenditure | -798.00K | -570.00K | -244.00K | -270.00K | -568.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 0.00 | -267.54M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -8.88M | -11.19M | 18.82M | -8.64M | -17.56M |
| Cash from Investing | -9.68M | -11.76M | -248.96M | -8.91M | -18.13M |
| Total Debt Issued | -- | 11.83M | 313.18M | -- | -- |
| Total Debt Repaid | -16.15M | -16.15M | -164.63M | -79.05M | -45.83M |
| Issuance of Common Stock | 2.06M | 173.00K | 620.00K | 5.72M | 4.56M |
| Repurchase of Common Stock | -10.59M | -25.30M | -142.00K | -40.88M | -12.87M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -555.00K | -11.83M | -- | -- | -- |
| Cash from Financing | -25.24M | -41.28M | 149.03M | -114.21M | -54.15M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 20.48M | 31.61M | -108.93M | -55.72M | -10.34M |